SANGAMO THERAPEUTICS INC (SGMO) Fundamental Analysis & Valuation

NASDAQ:SGMO • US8006771062

Current stock price

0.1192 USD
-0.01 (-10.24%)
At close:
0.123 USD
+0 (+3.19%)
After Hours:

This SGMO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SGMO Profitability Analysis

1.1 Basic Checks

  • In the past year SGMO has reported negative net income.
  • SGMO had a negative operating cash flow in the past year.
  • In the past 5 years SGMO always reported negative net income.
  • In the past 5 years SGMO always reported negative operating cash flow.
SGMO Yearly Net Income VS EBIT VS OCF VS FCFSGMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M

1.2 Ratios

  • SGMO has a worse Return On Assets (-205.76%) than 89.32% of its industry peers.
Industry RankSector Rank
ROA -205.76%
ROE N/A
ROIC N/A
ROA(3y)-152.69%
ROA(5y)-103.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SGMO Yearly ROA, ROE, ROICSGMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 -400 600 800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SGMO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMO Yearly Profit, Operating, Gross MarginsSGMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. SGMO Health Analysis

2.1 Basic Checks

  • SGMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SGMO has been increased compared to 1 year ago.
  • Compared to 5 years ago, SGMO has more shares outstanding
  • SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGMO Yearly Shares OutstandingSGMO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
SGMO Yearly Total Debt VS Total AssetsSGMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • SGMO has an Altman-Z score of -43.12. This is a bad value and indicates that SGMO is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -43.12, SGMO is doing worse than 91.84% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -43.12
ROIC/WACCN/A
WACC9.51%
SGMO Yearly LT Debt VS Equity VS FCFSGMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • SGMO has a Current Ratio of 0.84. This is a bad value and indicates that SGMO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.84, SGMO is doing worse than 88.16% of the companies in the same industry.
  • SGMO has a Quick Ratio of 0.84. This is a bad value and indicates that SGMO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • SGMO has a worse Quick ratio (0.84) than 87.96% of its industry peers.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.84
SGMO Yearly Current Assets VS Current LiabilitesSGMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. SGMO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.38% over the past year.
  • Looking at the last year, SGMO shows a very negative growth in Revenue. The Revenue has decreased by -32.14% in the last year.
  • SGMO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -19.66% yearly.
EPS 1Y (TTM)15.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-32.14%
Revenue growth 3Y-29.17%
Revenue growth 5Y-19.66%
Sales Q2Q%88.43%

3.2 Future

  • SGMO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.91% yearly.
  • SGMO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 55.51% yearly.
EPS Next Y49.46%
EPS Next 2Y35.28%
EPS Next 3Y37.28%
EPS Next 5Y31.91%
Revenue Next Year35.27%
Revenue Next 2Y54.49%
Revenue Next 3Y64.45%
Revenue Next 5Y55.51%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SGMO Yearly Revenue VS EstimatesSGMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
SGMO Yearly EPS VS EstimatesSGMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. SGMO Valuation Analysis

4.1 Price/Earnings Ratio

  • SGMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGMO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMO Price Earnings VS Forward Price EarningsSGMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMO Per share dataSGMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • SGMO's earnings are expected to grow with 37.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.28%
EPS Next 3Y37.28%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SGMO Dividend Analysis

5.1 Amount

  • SGMO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SGMO Fundamentals: All Metrics, Ratios and Statistics

SANGAMO THERAPEUTICS INC

NASDAQ:SGMO (4/30/2026, 9:21:31 PM)

After market: 0.123 +0 (+3.19%)

0.1192

-0.01 (-10.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-30
Earnings (Next)05-18
Inst Owners15.14%
Inst Owner Change-0.94%
Ins Owners0.92%
Ins Owner Change-10.84%
Market Cap49.38M
Revenue(TTM)39.55M
Net Income(TTM)-122.93M
Analysts80
Price Target3.89 (3163.42%)
Short Float %10.54%
Short Ratio6.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-31808.4%
Min EPS beat(2)-63537.1%
Max EPS beat(2)-79.74%
EPS beat(4)1
Avg EPS beat(4)-15895.9%
Min EPS beat(4)-63537.1%
Max EPS beat(4)38.49%
EPS beat(8)2
Avg EPS beat(8)-7926.16%
EPS beat(12)3
Avg EPS beat(12)-5289.44%
EPS beat(16)7
Avg EPS beat(16)-3964.33%
Revenue beat(2)0
Avg Revenue beat(2)-64.81%
Min Revenue beat(2)-98.34%
Max Revenue beat(2)-31.29%
Revenue beat(4)0
Avg Revenue beat(4)-46.97%
Min Revenue beat(4)-98.34%
Max Revenue beat(4)-14.91%
Revenue beat(8)1
Avg Revenue beat(8)-31.53%
Revenue beat(12)2
Avg Revenue beat(12)12.48%
Revenue beat(16)4
Avg Revenue beat(16)10.27%
PT rev (1m)0%
PT rev (3m)17.31%
EPS NQ rev (1m)107.9%
EPS NQ rev (3m)107.9%
EPS NY rev (1m)21.01%
EPS NY rev (3m)33.94%
Revenue NQ rev (1m)64.11%
Revenue NQ rev (3m)64.11%
Revenue NY rev (1m)66.44%
Revenue NY rev (3m)85.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.25
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.1
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -205.76%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-152.69%
ROA(5y)-103.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.58%
Cap/Sales 0.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.84
Altman-Z -43.12
F-Score3
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)49.41%
Cap/Depr(5y)112.61%
Cap/Sales(3y)4.24%
Cap/Sales(5y)10.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y49.46%
EPS Next 2Y35.28%
EPS Next 3Y37.28%
EPS Next 5Y31.91%
Revenue 1Y (TTM)-32.14%
Revenue growth 3Y-29.17%
Revenue growth 5Y-19.66%
Sales Q2Q%88.43%
Revenue Next Year35.27%
Revenue Next 2Y54.49%
Revenue Next 3Y64.45%
Revenue Next 5Y55.51%
EBIT growth 1Y25.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.79%
EBIT Next 3Y56.01%
EBIT Next 5Y47.6%
FCF growth 1Y-44.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.79%
OCF growth 3YN/A
OCF growth 5YN/A

SANGAMO THERAPEUTICS INC / SGMO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SANGAMO THERAPEUTICS INC (SGMO) stock?

ChartMill assigns a fundamental rating of 1 / 10 to SGMO.


What is the valuation status for SGMO stock?

ChartMill assigns a valuation rating of 1 / 10 to SANGAMO THERAPEUTICS INC (SGMO). This can be considered as Overvalued.


What is the profitability of SGMO stock?

SANGAMO THERAPEUTICS INC (SGMO) has a profitability rating of 0 / 10.


What is the earnings growth outlook for SANGAMO THERAPEUTICS INC?

The Earnings per Share (EPS) of SANGAMO THERAPEUTICS INC (SGMO) is expected to grow by 49.46% in the next year.